---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-096313"
form_type: "8-K"
ticker: "STRO"
cik: "0001382101"
company_name: "SUTRO BIOPHARMA, INC."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:38:55.020555+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sutro reports Q2 revenue $25.7M, cash $426M; luvelta trials advancing

## Summary
- Revenue $25.7M (up from $10.4M YoY) driven by Astellas collaboration and Vaxcyte agreement.
- Cash, equivalents, and securities $375.6M; Vaxcyte stock fair value $50.4M (total $426M).
- Operating expenses $74.4M (R&D $62.0M, G&A $12.4M); includes non-cash stock comp and depreciation.
- Luvelta Phase 3 REFRαME-O1 randomized portion underway; pediatric AML trial (REFRαME-P1) expected H2 2024.
- Appointed Sukhi Jagpal to Board and Barbara Leyman as Chief Business Development Officer.

## SEC filing metadata
- accession: 0000950170-24-096313
- form_type: 8-K
- ticker: STRO
- cik: 0001382101
- company_name: SUTRO BIOPHARMA, INC.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382101/000095017024096313/0000950170-24-096313-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382101/000095017024096313/stro-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-096313
- JSON: https://secwatch.observer/filing/0000950170-24-096313.json
- Plain text: https://secwatch.observer/filing/0000950170-24-096313.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.